Pretomanid-resistant tuberculosis

•Moxifloxacin daily doses of 2400 mg were tolerated over several months.•M. tuberculosis drug resistance could be overcome by a high-dose treatment regimen.•No occurrence of cardiac AEs despite high doses of QTc interval prolonging drugs.•No eradication of M. tuberculosis despite longstanding cultur...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infection 2023-05, Vol.86 (5), p.520-524
Main Authors: Koehler, Niklas, Andres, Sönke, Merker, Matthias, Dreyer, Viola, John, Agnieszka, Kuhns, Martin, Krieger, David, Choong, Eva, Verougstraete, Nick, zur Wiesch, Pia Abel, Wicha, Sebastian G., König, Christina, Kalsdorf, Barbara, Sanchez Carballo, Patricia M., Schaub, Dagmar, Werngren, Jim, Schön, Thomas, Peloquin, Charles A., Schönfeld, Nicolas, Verstraete, Alain G., Decosterd, Laurent A., Aarnoutse, Rob, Niemann, Stefan, Maurer, Florian P., Lange, Christoph
Format: Article
Language:English
Subjects:
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Humans
Nitroimidazoles
Tuberculosis - drug therapy
Tuberculosis, Multidrug-Resistant - drug therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Moxifloxacin daily doses of 2400 mg were tolerated over several months.•M. tuberculosis drug resistance could be overcome by a high-dose treatment regimen.•No occurrence of cardiac AEs despite high doses of QTc interval prolonging drugs.•No eradication of M. tuberculosis despite longstanding culture conversion.•Development of pretomanid resistance on an insufficient treatment regimen.
ISSN:0163-4453
1532-2742
1532-2742
DOI:10.1016/j.jinf.2023.01.039